AC Immune (ACIU) Stock Price, News & Analysis

Company Overview

AC Immune SA (NASDAQ: ACIU) is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland. Founded in 2003, the company develops precision medicines and diagnostic products designed to prevent, diagnose and treat neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease and other conditions associated with misfolded proteins.

AC Immune’s research is based on its SupraAntigen and Morphomer technology platforms, which are intended to identify disease-related proteins and generate therapies or diagnostic tools that target them. Its pipeline has included vaccine and antibody-based approaches aimed at amyloid-beta and tau, as well as programs addressing other proteins linked to neurodegeneration. The company has also pursued collaborations with larger pharmaceutical companies to advance selected candidates.

AC Immune serves the global biopharmaceutical and healthcare markets through research and development conducted primarily in Switzerland and through international partnerships and clinical studies. Andrea Pfeifer has served as the company’s chief executive officer and has been associated with its leadership since its early development.

Key Stats

• Today's Range: $2.63 to $2.81
• 50-Day Range: $2.18 to $2.93
• 52-Week Range: $2.10 to $4.00
• Volume: 68,460 shs
• Average Volume: 167,657 shs
• Market Capitalization: $267.66 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.50
• Consensus Rating: Moderate Buy

AC Immune Stock Analysis - MarketRank™

AC Immune scored higher than 45% of companies evaluated by MarketBeat, and ranked 572nd out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

AC Immune has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

AC Immune has a consensus price target of $7.50, representing about 185.2% upside from its current price of $2.63.

Amount of Analyst Coverage

AC Immune has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for AC Immune are expected to grow in the coming year, from ($0.60) to $0.17 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of AC Immune is -4.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of AC Immune is -4.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

AC Immune has a P/B Ratio of 4.87. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

3.39% of the float of AC Immune has been sold short.

Short Interest Ratio / Days to Cover

AC Immune has a short interest ratio ("days to cover") of 14.99, which indicates bearish sentiment.

Change versus previous month

Short interest in AC Immune has recently decreased by 3.22%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

AC Immune does not currently pay a dividend.

Dividend Growth

AC Immune does not have a long track record of dividend growth.

News and Social Media

• Score: 1.3 / 5
• News Sentiment: N/A

Search Interest

3 people have searched for ACIU on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.

MarketBeat Follows

1 people have added AC Immune to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, AC Immune insiders have not sold or bought any company stock.

Percentage Held by Insiders

4.60% of the stock of AC Immune is held by insiders.

Percentage Held by Institutions

51.36% of the stock of AC Immune is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 9/20/2026
• Next Earnings (Estimated): 11/03/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ACIU
• CIK: 1651625
• Web: www.acimmune.com
• Phone: (121) 345-9121
• Fax: 41-21-345-9120
• Employees: 106
• Year Founded: 2003

Price Target and Rating

• Average Price Target for AC Immune: $7.50
• High Price Target: $8.00
• Low Price Target: $7.00
• Potential Upside/Downside: +185.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.54)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$85.03 million
• Net Margins: -245.32%
• Pretax Margin: -1,796.18%
• Return on Equity: -100.17%
• Return on Assets: -28.36%

Debt

• Debt-to-Equity Ratio: 0.11
• Current Ratio: 0.93
• Quick Ratio: 1.02

Sales & Book Value

• Annual Sales: $4.31 million
• Price / Sales: 62.10
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.54 per share
• Price / Book: 4.87

Miscellaneous

• Outstanding Shares: 101,770,000
• Free Float: 97,092,000
• Market Cap: $267.66 million
• Optionable: Optionable
• Beta: 1.60